🛡️ Safety for Special Populations
Comprehensive Risk Assessment and Tailored Safety Protocols for Vulnerable Groups
📋 About This Guide
This guide provides specialized safety information for populations with unique physiological, psychological, or social vulnerabilities when considering psilocybin use. While general safety principles apply to everyone, certain groups require additional considerations, modified protocols, or may face absolute contraindications.
Key Principle: "First, do no harm." When in doubt about safety for a particular individual, consultation with medical professionals and conservative approach are always preferred.
👥 Age-Based Populations
🧓 Older Adults (65+)
⚠️ Elevated Risk Factors
- Cardiovascular System: Age-related changes increase risk of hypertensive crisis, arrhythmias, or ischemic events with sympathetic activation
- Medication Interactions: Polypharmacy common in older adults; many medications interact with psilocybin
- Cognitive Changes: Pre-existing mild cognitive impairment may be amplified during experience
- Fall Risk: Balance and coordination changes more pronounced; higher risk of serious injury from falls
- Slower Metabolism: Drug clearance reduced, potentially prolonging effects
Pre-Experience Medical Screening (Essential for 65+)
- Complete cardiovascular evaluation within past 6 months
- Resting ECG to rule out arrhythmias or ischemic changes
- Blood pressure control documented (target <140/90)
- Comprehensive medication review with pharmacist or physician
- Cognitive baseline assessment (MOCA or similar)
- Renal function tests (affects drug clearance)
- Bone density assessment if history of osteoporosis (fall risk)
Specific Safety Protocols for Older Adults
Dosage Modification: Start with 50-70% of standard adult dose. Example: if typical dose is 2g, start with 1-1.5g. Titrate slowly based on response.
Extended Monitoring: Vital signs (BP, HR, temperature) checked every 30 minutes during peak (90 minutes - 3 hours post-dose), then hourly until baseline.
Environment Modification:
- Remove all trip hazards (rugs, cords, clutter)
- Ensure bathroom easily accessible (no stairs if possible)
- Keep lights on low rather than complete darkness (reduces disorientation)
- Have walker or cane accessible if normally used
- Two trip sitters recommended (one can assist with mobility)
Cardiovascular Precautions:
- Baseline vital signs: BP <140/90, HR 60-90 bpm
- Emergency threshold: BP >180/110 or HR >120 sustained = call physician
- Have prescribed nitroglycerin accessible if history of angina
- Benzodiazepines available (physician-prescribed) for hypertensive response
✅ Positive Considerations for Older Adults
Despite increased risks, older adults may benefit uniquely from psychedelic experiences:
- End-of-Life Anxiety: Psilocybin shown effective for existential distress in terminal illness
- Life Review: Older adults often have rich life experience to process and integrate
- Treatment-Resistant Depression: May have tried many conventional treatments without success
- Wisdom and Maturity: Life experience can provide psychological resources for navigating challenging experiences
Research Note: Clinical trials at NYU and Johns Hopkins have included participants in their 60s-70s with careful screening and monitoring, showing safety and efficacy.
👶 Youth and Young Adults (Under 25)
🚨 Critical Developmental Considerations
Brain Development: Prefrontal cortex (executive function, decision-making, impulse control) not fully developed until mid-20s. Psychedelics impact areas still undergoing maturation.
Psychiatric Vulnerability: Ages 15-25 are peak onset period for schizophrenia, bipolar disorder, and other serious psychiatric conditions. Psychedelic use during prodromal phase may precipitate or worsen illness.
⛔ Age-Based Recommendations
Under 18
STRONG CONTRAINDICATION
Brain actively developing. Legal/ethical concerns. Wait until adulthood.
Ages 18-21
HIGH CAUTION
Consider deferring unless therapeutic context with professional supervision.
Ages 21-25
MODERATE CAUTION
Enhanced screening for psychiatric vulnerability. Conservative dosing.
Enhanced Psychiatric Screening for Young Adults
Red Flags Requiring Deferral
- Personal history of psychotic episode, mania, or severe depressive episode with psychotic features
- First-degree relative (parent, sibling) with schizophrenia or bipolar disorder
- Recent emergence of unusual beliefs, paranoia, or perceptual disturbances
- Severe anxiety or panic disorder poorly controlled
- Active suicidal ideation
- Substance use disorder (especially cannabis, stimulants, alcohol)
- Major life stressors or trauma within past 3-6 months
If Proceeding with Young Adult (21-25)
Dosage: Start low (1-1.5g psilocybin mushrooms maximum for first experience). Assess response before any future increases.
Set and Setting:
- Avoid party/festival environments for first experience
- Private, controlled setting with experienced trip sitter
- Daytime preferred (disrupted sleep schedule common in this age group)
- Limit group size (max 2-3 people total)
Psychiatric Monitoring:
- Check-in at 24 hours, 1 week, and 1 month post-experience
- Screen for: persistent perceptual changes, mood instability, paranoia, unusual beliefs
- Immediate psychiatric evaluation if any concerning symptoms emerge
- Integrate experience with therapist if possible
⚠️ Peer Pressure and Decision-Making
Young adults particularly vulnerable to peer influence. Ensure decision is autonomous, informed, and not coerced. "Everyone's doing it" or "trying to fit in" are poor reasons to use psychedelics.
Maturity Assessment: Can person articulate: why they want this experience, what they hope to gain, risks involved, and how they'll handle challenges? If not, may not be ready regardless of age.
🤰 Pregnancy, Breastfeeding, and Reproductive Health
⛔ ABSOLUTE CONTRAINDICATIONS
🚨 Pregnancy (All Trimesters)
Why Contraindicated:
- Placental Transfer: Psilocybin and psilocin cross placental barrier, exposing developing fetus
- Unknown Teratogenicity: No adequate studies on fetal effects. Cannot rule out birth defects or developmental abnormalities
- Serotonin System Development: Fetal brain development involves serotonin signaling. Disruption could affect neural development
- Maternal Stress: Challenging psychedelic experience causes significant stress response, potentially harmful to fetus
- Fall/Injury Risk: Coordination impairment during pregnancy already elevated; psychedelics significantly increase fall risk
If Accidental Exposure During Pregnancy:
- Do not panic - single exposure unlikely to cause harm but cannot be ruled out
- Contact obstetrician immediately for counseling and monitoring
- Document timing, dose, circumstances for medical records
- Enhanced prenatal monitoring may be recommended (ultrasounds, etc.)
- Genetic counseling available if concerns about fetal effects
🚨 Breastfeeding
Why Contraindicated:
- Milk Transfer: Psilocybin/psilocin excreted in breast milk (based on pharmacokinetic properties)
- Infant Exposure: No data on effects on infant brain development
- Maternal Impairment: Cannot safely care for infant while under psychedelic effects
- Unknown Dosing: Impossible to determine infant dose via breast milk
If Must Use While Breastfeeding (NOT RECOMMENDED):
- Pump and discard breast milk for minimum 24 hours post-ingestion (longer safer)
- Have adequate formula supply and feeding plan
- Infant in care of sober, competent adult for 24+ hours
- Consult lactation specialist about resuming breastfeeding timeline
Better Option: Defer psychedelic use until after breastfeeding is complete.
Trying to Conceive
Recommendation: Avoid psilocybin use once actively trying to conceive (both partners).
Male Partners:
- Sperm production cycle ~74 days. Theoretically, avoid 3 months before conception attempts.
- No definitive evidence of sperm effects, but conservative approach prudent.
Female Partners:
- Avoid during any cycle where pregnancy possible (after ovulation until confirmed not pregnant)
- Early pregnancy (before missed period) is critical developmental period
- Use reliable contraception if using psychedelics and not trying to conceive
🧠 Psychiatric Conditions
Schizophrenia and Psychotic Disorders
⛔ ABSOLUTE CONTRAINDICATION
Personal or Family History of Psychotic Disorders
Includes: Schizophrenia, schizoaffective disorder, delusional disorder, schizophreniform disorder, brief psychotic disorder
Why Absolutely Contraindicated:
- Precipitation of Psychosis: Psychedelics can trigger first psychotic episode in vulnerable individuals
- Exacerbation: Can worsen existing psychotic symptoms, potentially causing lasting destabilization
- Genetic Risk: First-degree relatives of people with schizophrenia have 10-15% lifetime risk (vs. 1% general population)
- Prodromal Phase: Many people in their teens-20s are in prodromal phase (pre-psychotic symptoms) without knowing it. Psychedelics can push into full illness.
Case Example: Previously healthy 22-year-old with maternal uncle with schizophrenia takes high-dose psilocybin. Develops persistent delusions and auditory hallucinations lasting months, eventually diagnosed with schizophrenia. While impossible to know if illness would have emerged anyway, psychedelics may have accelerated or triggered onset.
⚠️ Screening Questions to Identify Risk
Ask yourself or person considering use:
- Have you ever experienced hallucinations (seeing or hearing things others don't) when NOT using drugs?
- Have you ever felt people were plotting against you or talking about you?
- Have you ever felt you had special powers or a special mission?
- Has anyone in your immediate family (parent, sibling, child) been diagnosed with schizophrenia or psychosis?
- Have you ever been hospitalized for psychiatric reasons?
- Have you ever been told you have "strange" or "bizarre" thoughts?
If YES to any: Strongly reconsider psychedelic use. Consultation with psychiatrist essential before proceeding.
Bipolar Disorder
⚠️ STRONG RELATIVE CONTRAINDICATION
Risk: Psychedelics can precipitate manic or hypomanic episodes.
Considerations:
- Type I Bipolar (with manic episodes): Higher risk; generally not recommended
- Type II Bipolar (hypomania only): Moderate risk; requires careful consideration
- Well-Controlled: If on mood stabilizers and stable for >1 year, may consider with psychiatric supervision
- Active Symptoms: If currently manic, hypomanic, or in depressive episode - absolutely defer
If Proceeding (Therapeutic Context Only)
Essential Precautions for Bipolar Disorder
- Psychiatric evaluation within 1 month confirming stability
- Remain on mood stabilizers (lithium, valproate, lamotrigine) - do NOT discontinue
- Low dose only (1g or less for first experience)
- Therapeutic setting with mental health professional present
- Daily monitoring for 1 week post-experience (mood, sleep, energy, speech rate)
- Immediate psychiatric contact if early signs of mania (decreased sleep need, rapid speech, increased energy/goal-directed activity)
- Family/close contacts briefed to watch for manic symptoms
Sleep Monitoring Post-Experience
Decreased sleep need is often first sign of emerging mania. Track: time to bed, time to sleep, wake time, total sleep hours.
Red Flag: Sleeping <6 hours for 2+ consecutive nights AND feeling rested/energized = contact psychiatrist immediately.
Depression and Anxiety Disorders
✅ Potentially Beneficial with Appropriate Precautions
Unlike psychotic or bipolar disorders, depression and anxiety disorders may actually benefit from psilocybin therapy, with substantial research support.
Major Depressive Disorder (MDD)
Research Support: Multiple clinical trials show psilocybin-assisted therapy effective for treatment-resistant depression.
Safe to Proceed If:
- No psychotic features (no delusions, hallucinations)
- No active suicidal plan or intent (passive ideation okay with proper support)
- Adequate support system and crisis plan in place
- Not currently in acute crisis requiring immediate psychiatric care
Enhanced Precautions:
- Trip sitter trained in suicide assessment and crisis intervention
- Clear crisis plan: who to call, when to call 911
- Remove access to means of self-harm during and 24 hours post-experience
- Integration therapy essential - psychedelics not "magic cure," need processing
- If on antidepressants, discuss with prescriber about tapering (see medication section)
Anxiety Disorders (GAD, Social Anxiety, Panic Disorder)
Paradox: Psychedelics can cause short-term anxiety (during experience) while potentially reducing long-term anxiety (weeks-months after).
Considerations:
- Panic Disorder: May experience panic during trip; need strong reassurance and grounding techniques available
- Social Anxiety: Generally good candidate if proper support; avoid social settings during experience
- GAD: May benefit, but ensure benzodiazepines available for severe anxiety during trip
Set and Setting Optimization:
- Familiar, comfortable environment (home preferred over unfamiliar location)
- Trusted trip sitter experienced with anxiety management
- Benzodiazepine (prescribed by doctor) available as "escape hatch" if needed
- Moderate dose initially (1.5-2g) rather than high dose
- Pre-experience anxiety management plan discussed and practiced
Post-Traumatic Stress Disorder (PTSD)
⚠️ Proceed with Caution - Therapeutic Context Strongly Preferred
Potential: Psilocybin may help process trauma, but also risk of re-traumatization if not properly supported.
Requirements for PTSD:
- Therapeutic Setting: Trained trauma therapist present strongly recommended
- Stabilization First: Person should have basic emotion regulation skills before psychedelic work
- Complex PTSD: Developmental trauma, dissociative symptoms - requires specialized expertise
- Safety Plan: Extensive preparation about what to do if traumatic memories surface
- Integration Critical: Multiple therapy sessions post-experience to process material that emerged
Red Flags - Defer Psychedelic Use:
- Active dissociation or derealization/depersonalization symptoms
- Self-harm behaviors or suicide attempts within past 6 months
- No established relationship with trauma therapist
- Recreational context without therapeutic support
- Recent traumatic event (within 3-6 months) - need stabilization first
🏥 Medical Conditions
❤️ Cardiovascular Disease
⚠️ Significant Risk - Medical Evaluation Essential
Physiological Effect: Psilocybin causes mild-moderate sympathetic activation: increased heart rate (typically 10-20 bpm), increased blood pressure (typically 10-20 mmHg), and increased myocardial oxygen demand.
In healthy hearts: Easily tolerated.
In diseased hearts: Could precipitate ischemia, arrhythmia, or other events.
| Condition | Risk Level | Recommendations |
|---|---|---|
| Hypertension (Well-Controlled) | Moderate |
• BP must be <140/90 on medications • Continue all BP medications • Vital sign monitoring during experience • Benzodiazepines available to reduce BP if needed • Cardiology clearance if BP >150/95 or on multiple meds |
| Hypertension (Poorly Controlled) | High |
• Defer until BP controlled • Risk of hypertensive crisis, stroke • Optimize medical management first |
| Coronary Artery Disease (CAD) | High |
• History of MI: defer for 6-12 months post-event • Stable CAD: cardiology clearance required, stress test normal • Nitroglycerin immediately available • Physician on-call during experience • Consider medical setting only |
| Arrhythmias | High |
• Atrial fibrillation (controlled on meds): moderate risk, cardiology clearance • Ventricular arrhythmias: defer • Pacemaker/ICD: cardiology consultation essential • Continuous cardiac monitoring may be needed |
| Heart Failure | Very High |
• Generally not recommended • If considering: only in medical setting with cardiology support • Risk of decompensation from increased cardiac demand |
| Valvular Heart Disease | Moderate to High |
• Depends on severity • Mild disease: may proceed with cardiology clearance • Moderate-severe: defer or medical setting only |
Cardiovascular Safety Protocol
- Cardiology evaluation within 3-6 months including ECG, possibly stress test
- Baseline vital signs: BP <140/90, HR 60-90, no chest pain
- Continue all cardiac medications day of experience
- Vital signs checked: baseline, 30 min post-dose, peak (90-120 min), then hourly
- Emergency medications available: aspirin, nitroglycerin, benzodiazepines
- Physician phone number immediately available
- Trip sitter trained in recognizing cardiac emergencies
- Low-moderate dose only (avoid high doses increasing cardiovascular strain)
- Emergency services (911) called if: chest pain, severe dyspnea, BP >180/110 sustained, HR >130 sustained
🧠 Neurological Conditions
Epilepsy and Seizure Disorders
⚠️ Proceed with Significant Caution
Complex Relationship: Limited data on psilocybin and seizure threshold. Theoretical concerns both ways:
- Potential Risk: Sensory stimulation during trip could trigger seizures in photosensitive epilepsy
- Potential Benefit: Some psychedelics historically used (questionably) for cluster headaches; mechanisms unclear
If Proceeding:
- Epilepsy must be well-controlled (no seizures in past 12 months)
- Continue all anti-epileptic medications (AEDs) - never skip doses
- Neurology consultation and clearance essential
- Trip sitter trained in seizure first aid
- Rescue benzodiazepines (if prescribed) immediately accessible
- Avoid strobe lights, intense visual stimulation
- Adequate sleep night before (sleep deprivation lowers seizure threshold)
- Emergency services called for any seizure activity
Migraine Disorders
Interesting Relationship - Potential Therapeutic
Cluster Headaches: Anecdotal reports and some small studies suggest psilocybin (and LSD) may reduce cluster headache frequency. Some patients use sub-hallucinogenic doses for this purpose.
Migraines: Mixed reports. Some find psychedelics trigger migraines; others report reduction in frequency post-experience.
Recommendations:
- Generally safe to proceed with migraine history
- Have abortive migraine medications available (triptans - but see interaction section)
- Avoid experience during migraine or in prodromal phase
- Some patients report migraine triggered 24-48 hours post-experience
Multiple Sclerosis (MS) and Other Demyelinating Disorders
Limited Data: No specific contraindication, but considerations:
- Fatigue: Psychedelic experiences physically tiring; may worsen MS fatigue
- Temperature Sensitivity: Some MS patients sensitive to temperature changes; monitor thermal comfort
- Mobility: Ensure safe environment for limited mobility if applicable
- Medications: Many MS drugs (immunomodulators, corticosteroids) - review interactions
Generally acceptable with appropriate precautions and medical consultation.
🩸 Immunocompromised Individuals
⚠️ Infection Risk from Mushrooms
Primary Concern: Not psilocybin itself, but potential bacterial/fungal contamination of mushrooms.
High-Risk Populations:
- HIV/AIDS with low CD4 count (<200)
- Organ transplant recipients on immunosuppression
- Chemotherapy patients (neutropenic)
- Chronic corticosteroid use (>20mg prednisone daily for >2 weeks)
- Autoimmune diseases on immunosuppressants (biologics, etc.)
Risk Mitigation:
- Synthetic Psilocybin: If available through clinical trial, eliminates contamination risk
- Properly Cultivated Mushrooms: Home-grown with sterile technique safer than wild-foraged or unknown source
- Avoid Wild Mushrooms: Higher contamination and misidentification risk
- Inspect Carefully: Discard any mushrooms with visible mold, slime, or off-odor
- Consider Extraction: Tea preparation with boiling water may reduce bacterial load (but not eliminate)
Psilocybin in Terminally Ill Patients
Research Context: Most clinical research on psilocybin for end-of-life anxiety included cancer patients, many immunocompromised from chemotherapy.
Key Finding: When using pharmaceutical-grade synthetic psilocybin in controlled settings, no increased infection risk observed.
Implication: Risk is from contaminated mushrooms, not psilocybin itself. Medical-grade psilocybin can be safely used in immunocompromised patients.
🍽️ Gastrointestinal and Metabolic Conditions
Diabetes (Type 1 and Type 2)
Generally Safe with Precautions:
- Blood Glucose Monitoring: Check glucose before, during (at 2 hours), and after experience
- Nausea Effect: Psilocybin commonly causes nausea; may affect eating and blood sugar
- Insulin/Medications: Continue all diabetes medications; have fast-acting glucose available
- Timing: Start experience after light meal to stabilize blood sugar
- Trip Sitter: Should know how to recognize and treat hypoglycemia
- Glucagon Kit: If type 1 diabetic, ensure glucagon emergency kit accessible
Liver Disease
Moderate Caution: Psilocybin metabolized by liver; severe liver disease may prolong effects.
- Mild Liver Disease: Generally acceptable; standard dosing
- Moderate Liver Disease: Consider dose reduction (25-30%); effects may be prolonged
- Severe Liver Disease (Cirrhosis): Limited data; conservative approach recommended. Medical consultation essential.
Kidney Disease
Generally Safe: Psilocin excreted primarily in urine, but renal impairment does not significantly affect pharmacokinetics at typical doses.
- Ensure adequate hydration before and during experience
- Continue all kidney-related medications
- Dialysis patients: can use psilocybin; timing relative to dialysis not critical
💊 Medication Interactions
🚨 Critical Drug Interactions - Can Be Dangerous
Psilocybin's serotonergic activity creates potential for dangerous interactions with other serotonergic drugs. Additionally, some medications can significantly alter psychedelic effects.
| Medication Class | Interaction Type | Risk Level | Recommendation |
|---|---|---|---|
| MAOIs (Monoamine Oxidase Inhibitors) Examples: Phenelzine (Nardil), Tranylcypromine (Parnate), Selegiline (Emsam) |
Serotonin Syndrome Risk | VERY HIGH |
CONTRAINDICATED • MAOIs prevent breakdown of serotonin • Combined with psilocybin = dangerous serotonin excess • Must discontinue MAOIs for 2 weeks before psilocybin • Only taper MAOIs under psychiatric supervision |
| SSRIs (Selective Serotonin Reuptake Inhibitors) Examples: Fluoxetine (Prozac), Sertraline (Zoloft), Escitalopram (Lexapro), Paroxetine (Paxil), Citalopram (Celexa) |
Reduced Psychedelic Effect + Small Serotonin Syndrome Risk | MODERATE |
Complicated • SSRIs reduce psilocybin effects (blunt the experience) • Small risk of serotonin syndrome (uncommon but possible) • Many prefer to taper off SSRIs before psilocybin therapy • NEVER stop SSRIs abruptly - requires gradual taper over weeks • Consult prescribing physician before any changes • If staying on SSRIs: may need higher psilocybin dose; monitor for serotonin syndrome symptoms |
| SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors) Examples: Venlafaxine (Effexor), Duloxetine (Cymbalta), Desvenlafaxine (Pristiq) |
Similar to SSRIs | MODERATE |
Same recommendations as SSRIs: • Reduce psychedelic effects • Small serotonin syndrome risk • Taper gradually if discontinuing (under medical supervision) |
| Lithium Used for bipolar disorder |
Seizure Risk | VERY HIGH |
CONTRAINDICATED by many experts • Case reports of seizures when combining lithium + psychedelics • Mechanism unclear but risk appears real • If must use psilocybin while on lithium: only in medical setting with seizure precautions • DO NOT stop lithium for psychedelic use - risk of manic episode • Consult psychiatrist; consider alternative mood stabilizer |
| Tricyclic Antidepressants (TCAs) Examples: Amitriptyline (Elavil), Nortriptyline (Pamelor), Imipramine (Tofranil) |
Reduced Effects + Cardiovascular | MODERATE |
• TCAs may reduce psychedelic effects • TCAs have cardiovascular effects (see cardio section) • Combination increases cardiac monitoring need • Taper with physician guidance if discontinuing |
| Benzodiazepines Examples: Alprazolam (Xanax), Lorazepam (Ativan), Clonazepam (Klonopin), Diazepam (Valium) |
Reduced Intensity (Trip-killer) | LOW |
Generally Safe - Actually Useful • Benzos reduce psychedelic intensity • Useful as "emergency brake" for overwhelming experiences • Can take benzos during trip to reduce anxiety • Daily benzo use may slightly reduce trip intensity • No dangerous interaction |
| Antipsychotics Examples: Risperidone (Risperdal), Olanzapine (Zyprexa), Quetiapine (Seroquel), Haloperidol (Haldol) |
Significantly Reduced or Blocked Effects | LOW (medically safe) |
• Antipsychotics block serotonin receptors that psilocybin activates • Will significantly diminish or completely block psychedelic effects • Not dangerous, but pointless to take psilocybin while on antipsychotics • DO NOT stop antipsychotics for psychedelic use - high risk of psychiatric relapse • If on antipsychotics, psychedelics generally not appropriate |
| Stimulants (ADHD Medications) Examples: Amphetamine (Adderall), Methylphenidate (Ritalin), Lisdexamfetamine (Vyvanse) |
Increased Cardiovascular Strain | MODERATE |
• Both stimulants and psilocybin increase HR/BP • Combination increases cardiovascular monitoring need • Consider skipping stimulant dose on psilocybin day • If taking both: enhanced vital sign monitoring • Some report stimulants increase anxiety during trip |
| Triptans (Migraine Medications) Examples: Sumatriptan (Imitrex), Rizatriptan (Maxalt) |
Small Serotonin Syndrome Risk | MODERATE |
• Triptans are serotonin agonists • Theoretical serotonin syndrome risk • Avoid taking triptan within 24 hours of psilocybin • Have alternative migraine medication available |
| Tramadol Opioid pain medication with serotonergic activity |
Serotonin Syndrome Risk | HIGH |
Avoid Combination • Tramadol has serotonin reuptake inhibition • Risk of serotonin syndrome • Use alternative pain medication if needed • Other opioids (morphine, oxycodone) do NOT have this risk |
📋 Pre-Experience Medication Review Checklist
- List ALL medications (prescription, over-the-counter, supplements, herbs)
- Check each medication against interaction list above
- Consult with prescribing physician or pharmacist about any concerns
- Never stop psychiatric medications abruptly - requires supervised taper
- Plan medication timing: which to take day-of, which to skip, which to adjust
- Have emergency medications available (benzodiazepines if prescribed, migraine meds, cardiac meds if applicable)
- Inform trip sitter of all medications in case emergency arises
⚠️ The Tapering Dilemma
Common Scenario: Person on SSRI for depression wants to try psilocybin therapy. Hears SSRIs blunt effects. Considers stopping SSRI.
Critical Considerations:
- Why on SSRI? If for depression/anxiety, stopping may cause relapse before psilocybin experience even happens
- Withdrawal: SSRI discontinuation syndrome is real and unpleasant (dizziness, "brain zaps," mood instability). Should not be experiencing this during psychedelic preparation
- Timing: SSRIs take 2-4 weeks to fully clear system. Can't just stop a few days before
- Psychiatric Instability: Tapering off SSRI creates period of vulnerability - not ideal time for intense psychedelic experience
Better Approach:
- Consult with prescribing psychiatrist about interest in psilocybin therapy
- If psychiatrist agrees, develop gradual taper plan over weeks-months
- Ensure stable mood throughout taper
- Wait 2-4 weeks after last SSRI dose before psilocybin
- Have clear plan for resuming SSRI if needed after psilocybin trial
- Integration therapy throughout process
Alternative: Some people successfully use psilocybin while on SSRIs, accepting reduced intensity. Requires higher dose and realistic expectations. Still valuable for some.
📊 Population Risk Summary Matrix
| Population | Risk Level | Primary Concern | Can Proceed? |
|---|---|---|---|
| Older Adults (65+) | Moderate | Cardiovascular events, falls | Yes, with medical screening and precautions |
| Youth (<18) | Very High | Brain development, psychiatric risk | Strong contraindication |
| Young Adults (18-25) | Moderate | Psychiatric onset window | Yes, with enhanced psychiatric screening |
| Pregnancy | Very High | Unknown fetal effects | Absolute contraindication |
| Breastfeeding | Very High | Infant exposure via milk | Absolute contraindication |
| Schizophrenia/Psychosis History | Very High | Psychotic episode precipitation | Absolute contraindication |
| Bipolar Disorder | High | Manic episode risk | Generally avoid; therapeutic context only if proceeding |
| Depression/Anxiety | Low | Psychological distress during trip | Yes, potentially beneficial with support |
| PTSD | Moderate | Re-traumatization | Therapeutic context strongly preferred |
| Cardiovascular Disease (Controlled) | Moderate | Ischemia, arrhythmia, BP crisis | Yes, with cardiology clearance and monitoring |
| Cardiovascular Disease (Severe/Uncontrolled) | Very High | Cardiac event | Generally avoid; medical setting only |
| Epilepsy (Well-Controlled) | Moderate | Seizure precipitation | Caution; neurology clearance |
| Immunocompromised | Moderate | Infection from contaminated mushrooms | Yes, with pharmaceutical-grade psilocybin or carefully sourced mushrooms |
| On MAOIs | Very High | Serotonin syndrome | Contraindicated without 2-week washout |
| On SSRIs/SNRIs | Moderate | Reduced effects, small SS risk | Complicated; can proceed with caveats |
| On Lithium | Very High | Seizure risk | Contraindicated by many experts |
| On Benzodiazepines | Low | Reduced intensity (beneficial) | Yes, safe and potentially helpful |